PriceTargets.com logo

NeuBase Therapeutics - NBSE Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.38 As of 09/20/2024 01:00 AM ET
+0 (0.00%)
Get New NeuBase Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NBSE and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NBSE

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for NeuBase Therapeutics in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $0.38.

This chart shows the closing price for NBSE for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 polled investment analysts is to n/a stock in NeuBase Therapeutics. This rating has held steady since September 2023, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/20/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/19/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/18/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/16/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/14/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/14/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/13/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/13/2025

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
10/21/2022OppenheimerDowngradeOutperform ➝ Market Perform
10/18/2022Royal Bank Of CanadaDowngradeOutperform ➝ Sector Perform
10/17/2022Chardan CapitalDowngradeBuy ➝ Neutral
8/23/2022OppenheimerLower Target$300.00
8/12/2022Chardan CapitalLower TargetBuy$180.00 ➝ $140.00
5/31/2022HC WainwrightLower TargetBuy$300.00 ➝ $200.00
5/13/2022Chardan CapitalLower Target$360.00 ➝ $180.00
1/3/2022HC WainwrightReiterated RatingBuy
9/13/2021HC WainwrightReiterated RatingBuy$300.00
6/1/2021HC WainwrightLower TargetBuy$360.00 ➝ $300.00
3/18/2021OppenheimerReiterated RatingBuy$340.00
2/12/2021HC WainwrightBoost TargetBuy$300.00 ➝ $360.00
12/27/2020Royal Bank Of CanadaReiterated RatingBuy$340.00
12/17/2020HC WainwrightReiterated RatingBuy
8/16/2020Royal Bank Of CanadaReiterated RatingBuy$320.00
8/14/2020Chardan CapitalReiterated RatingBuy
7/16/2020OppenheimerReiterated RatingBuy$340.00
(Data available from 7/13/2020 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/15/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/14/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/13/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/15/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/14/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/14/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/13/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/13/2025

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
NeuBase Therapeutics logo
NeuBase Therapeutics, Inc., a preclinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications. Its pipeline includes NT0100 for Huntington's disease; NT0200 for myotonic dystrophy type 1; and NT0300 treatment targets the mutated KRAS gene. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania.
Read More

Today's Range

Now: $0.38
Low: $0.38
High: $0.38

50 Day Range

MA: $0.38
Low: $0.38
High: $0.38

52 Week Range

Now: $0.38
Low: $0.36
High: $4.80

Volume

N/A

Average Volume

N/A

Market Capitalization

$1.43 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of NeuBase Therapeutics?

The following Wall Street analysts have issued stock ratings on NeuBase Therapeutics in the last twelve months:
View the latest analyst ratings for NBSE.

What is the current price target for NeuBase Therapeutics?

0 Wall Street analysts have set twelve-month price targets for NeuBase Therapeutics in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for NeuBase Therapeutics in the next year.
View the latest price targets for NBSE.

What is the current consensus analyst rating for NeuBase Therapeutics?

NeuBase Therapeutics currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for NBSE.

What other companies compete with NeuBase Therapeutics?

Other companies that are similar to NeuBase Therapeutics include Qualigen Therapeutics, Fresh Tracks Therapeutics, Pasithea Therapeutics, GT Biopharma and Ensysce Biosciences. Learn More about companies similar to NeuBase Therapeutics.

How do I contact NeuBase Therapeutics' investor relations team?

NeuBase Therapeutics' physical mailing address is 700 TECHNOLOGY DRIVE, PITTSBURGH PA, 15219. The company's listed phone number is (164) 645-1790 and its investor relations email address is [email protected]. The official website for NeuBase Therapeutics is www.neubasetherapeutics.com. Learn More about contacing NeuBase Therapeutics investor relations.